Chronic myeloid leukaemia articles from across Nature Portfolio

Chronic myeloid (or myelogenous) leukaemia (CML), also known as chronic granulocytic leukaemia, is a cancer of the white blood cells. It is characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood.

Latest Research and Reviews

Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations
- Nikola Curik
- Adam Laznicka
- Katerina Machova Polakova
ResearchOpen Access13 Apr 2024 Leukemia
P: 1-4
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
- Annamaria Brioli
- Elza Lomaia
- Michael Lauseker
ResearchOpen Access28 Mar 2024 Leukemia
P: 1-9
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
- Hagop Kantarjian
- Susan Branford
- Francois Xavier-Mahon
Reviews26 Mar 2024 Leukemia
P: 1-4
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
- Daniela Žáčková
- Lukáš Semerád
- Jiří Mayer
ResearchOpen Access12 Mar 2024 Leukemia
Volume: 38, P: 893-897
Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1 mediated purine sensing

The role of folate metabolism in leukemic stem cells remains understudied. Here, the authors show that inhibition of mitochondrial folate metabolism leads to differentiation of leukemic cells through depletion of purines and suppression of mTORC1.
- Martha M. Zarou
- Kevin M. Rattigan
- G. Vignir Helgason
ResearchOpen Access02 Mar 2024 Nature Communications
Volume: 15, P: 1931
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
- Simone Claudiani
- Farhan Chughtai
- Dragana Milojkovic
ResearchOpen Access29 Feb 2024 Leukemia
Volume: 38, P: 796-802

All Research & Reviews

News and Comment

A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
- Massimiliano Bonifacio
- Luigi Scaffidi
- Mario Tiribelli
CorrespondenceOpen Access26 Mar 2024 Blood Cancer Journal
Volume: 14, P: 53
Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy
- Yujie Liu
- Yuqing Tu
- Yang Xu
CorrespondenceOpen Access06 Mar 2024 Blood Cancer Journal
Volume: 14, P: 39
How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies
- Rüdiger Hehlmann
- Michael Lauseker
CorrespondenceOpen Access13 Jan 2024 Leukemia
Volume: 38, P: 465-466
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen
- Markus Pfirrmann
- Susanne Saussele
- Johan Richter
CorrespondenceOpen Access03 Jan 2024 Leukemia
Volume: 38, P: 460-462
Response to Pfirrmann et al.’s comment on How should we interpret conclusions of TKI-stopping studies
- Junren Chen
- Robert Peter Gale
CorrespondenceOpen Access27 Dec 2023 Leukemia
Volume: 38, P: 463-464
Luigi (Gino) Chieco-Bianchi: a man linking hematological and virological research
- Rüdiger Hehlmann
- Giuseppe Saglio
Comments & Opinion06 Dec 2023 Leukemia
Volume: 38, P: 233-234

All News & Comment

Chronic myeloid leukaemia articles from across Nature Portfolio

Latest Research and Reviews

Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1 mediated purine sensing

Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance

News and Comment

A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements

Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy

How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies

How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen

Response to Pfirrmann et al.’s comment on How should we interpret conclusions of TKI-stopping studies

Luigi (Gino) Chieco-Bianchi: a man linking hematological and virological research

Search

Quick links